Dieter Falkenburg
Amministratore Delegato presso Novoplant GmbH
Profilo
Dieter Falkenburg has been Chief Executive Officer of Novoplant GmbH since May 2004.
He joined ASTA Medica in 1990 as Manager of International Business Development.
He was appointed as Vice President of Business Development for MPB Cologne and Executive Vice President of Business Development for Direvo AG in 1999.
Dr. Falkenburg received a PhD from Ruprecht Karls University, Heidelberg.
Posizioni attive di Dieter Falkenburg
Società | Posizione | Inizio |
---|---|---|
Novoplant GmbH
Novoplant GmbH Agricultural Commodities/MillingProcess Industries Novoplant GmbH develops and provides veterinary medicines. It produces antibodies and antibody fragments in plants for veterinary use to fight intestinal pathogens. It received a license for the development and commercialization of therapeutic antibodies as feed components for use in veterinary medicine. It will use MorphoSys’s HuCAL GOLD technology to generate antibodies against viruses, parasites and pathogenic microorganisms. The addition of such antibodies to animal feed stock may offer protection against infectious diseases in the respective animal’s gastro-intestinal tract. The company was founded in 1998 and is headquartered in Gatersleben, Germany. | Amministratore Delegato | - |
Precedenti posizioni note di Dieter Falkenburg
Società | Posizione | Fine |
---|---|---|
ASTA Medica Oncology | Corporate Officer/Principal | - |
Formazione di Dieter Falkenburg
Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Novoplant GmbH
Novoplant GmbH Agricultural Commodities/MillingProcess Industries Novoplant GmbH develops and provides veterinary medicines. It produces antibodies and antibody fragments in plants for veterinary use to fight intestinal pathogens. It received a license for the development and commercialization of therapeutic antibodies as feed components for use in veterinary medicine. It will use MorphoSys’s HuCAL GOLD technology to generate antibodies against viruses, parasites and pathogenic microorganisms. The addition of such antibodies to animal feed stock may offer protection against infectious diseases in the respective animal’s gastro-intestinal tract. The company was founded in 1998 and is headquartered in Gatersleben, Germany. | Process Industries |
ASTA Medica Oncology |
- Borsa valori
- Insiders
- Dieter Falkenburg